Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02936102
Title A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

Advanced Solid Tumor

alveolar soft part sarcoma

triple-receptor negative breast cancer

Therapies

FAZ053

FAZ053 + Spartalizumab

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.